Nipro Corporation
Nipro Corporation
Your view on NPRRF
Overview
What the company does, where it operates, and who runs it.
About Nipro Corporation
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Yoshihiko Sano
- Headquarters
- 3-9-3 Honjo-nishi, Osaka, JP
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Yoshihiko Sano
- Headquarters
- 3-9-3 Honjo-nishi, Osaka, JP
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses.
The company's Medical Device business develops, manufactures, and sells medical equipment for injection-infusion and dialysis treatment, and products related to diabetes and cell cultures, as well as the sale of artificial organ-related products.
Its Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations, as well as logistic and distribution services.
The company's Pharma Packaging business offers glass products and other comprehensive pharmaceutical packaging, such as glass vials, ampoules, syringes, and cartridges; glass tubes; glass bulbs for vacuum flasks; and other parts of pharmaceutical packaging, such as rubber plugs.
Its Other business provides thermostable enzymes for clinical chemistry. The company also offers business management services. Nipro Corporation serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Osaka, Japan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nipro Corporation, and the rating behind it. NPRRF last traded at $8.23, 16.7× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nipro Corporation. Starting points for Nipro Corporation: P/E 16.7, EPS $86.04, beta 0.29 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nipro Corporation. Nipro Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nipro Corporation. Trailing twelve-month EPS for Nipro Corporation stands at $86.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nipro Corporation. Nipro Corporation has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nipro Corporation valued side by side against its closest peers. Nipro Corporation is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nipro Corporation, and how their positions are changing. At a $1.34B market value, institutional positions materially move Nipro Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nipro Corporation executives and directors. Shares of Nipro Corporation have traded between $8.23 and $8.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nipro Corporation. Nipro Corporation is a $1.34B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nipro Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nipro Corporation. Coverage tracks Nipro Corporation within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.